Repligen Corp.
41 Seyon Street Building 1
Suite 100
Waltham,
MA 02453
Phone: 781-250-0111
Fax: 781-250-0115
Web Site: http://www.repligen.com
| Repligen Corporation, a biopharmaceutical company, engages in the research and development of therapeutics for the treatment of central nervous system diseases. It manufactures and markets Protein A product, which is used in the production of various therapeutic monoclonal antibodies. The company also markets SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain diseases of the pancreas. Repligen sells Protein A products to chromatography companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers primarily through value-added resellers and distributors in the United States and internationally; and markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, such as bipolar disorder and neurodegeneration. Its development stage products include RG1068, a Phase II clinical trial product that improve the detection of structural abnormalities of the pancreatic ducts during MRI imaging of the pancreas; and RG2417, a Phase II clinical trial product, is a biological compound used for the synthesis of DNA and RNA in patients with bipolar depression. Repligen has a research and development agreement with the Stanley Medical Research Institute for the development of RG2417. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. |
|
| Key Statistics |
|
|
|
| |
Pay |
Exercised |
Dr. Alexander Rich M.D., 83
Co-Founder, Co-Chairman and Member of Nominating & Corp. Governance Committee
|
$
43.00K |
N/A |
Dr. Walter C. Herlihy Ph.D., 56
Chief Exec. Officer, Pres, Director and Member of Exec. Committee
|
$
416.00K |
$
85.00K |
Dr. Daniel P. Witt Ph.D., 61
VP of Operations
|
$
222.00K |
$
32.00K |
Dr. James R. Rusche Ph.D., 54
Sr. VP of R&D
|
$
265.00K |
$
34.00K |
Ms. Laura L. Whitehouse ,
VP of Market Devel.
|
N/A
|
N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
|
|
|
Help
Profile
